Core Insights - Molecular Partners AG presented new data on MP0712, a Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe, showcasing promising human imaging results and supporting mechanism of action data [1][2][3] Clinical Development - MP0712 is being developed in collaboration with Orano Med for treating small cell lung cancer (SCLC) and other neuroendocrine cancers, with a Phase 1 trial expected to start by the end of 2025 [1][7] - The Phase 1 Investigational New Drug (IND) application has been filed, and ongoing discussions with the FDA are taking place [7][8] Imaging and Efficacy - Initial imaging results indicate targeted delivery of MP0712 into tumors with minimal exposure to healthy organs, suggesting its potential effectiveness in a clinical setting [2][3] - A case study showed specific uptake in tumor lesions at 24 hours, sustained over four days, with limited accumulation in healthy organs [3][5] Mechanism of Action - MP0712 is engineered for half-life optimization to maintain drug levels in the blood, supporting its intended mechanism of action [3][6] - The data suggests that MP0712 can achieve high tumor uptake even with low DLL3 expression levels, leveraging internalization and optimal binding properties [6] Future Outlook - The company anticipates initial clinical data from the Phase 1/2a study in 2026, which will assess safety and determine a recommended phase 2 dose for MP0712 [7][8] - Molecular Partners is also advancing additional Radio-DARPin programs in 2026 [2][8] Technology and Innovation - The Radio-DARPin platform combines the targeting capabilities of DARPins with the therapeutic potential of 212Pb, aiming to improve the delivery of radioactive payloads to solid tumors [11] - DARPins are designed to offer high specificity and affinity, making them suitable for efficient delivery of therapeutic radionuclides [12]